ImmuneBiotech’s drug candidates provide a new means of resolving inflammatory and infectious diseases by re-establishing a healthy bacterial flora in the bowel. The candidates introduces unique strains of beneficial and immunomodulatory lactobacilli to change the gut microbiota composition and immune status of the patients.
Clostridium difficile infections
Clostridium difficile (CD) is part of a normal gut flora but can become a health threat for elderly hospitalized people, cancer patients, and patients under antimicrobial treatment. Under these conditions CD can overgrow and release toxins affecting the gut lining causing a severe form of colitis. In the US alone CD cause 500,000 infections annually and 29,000 deaths within 30 days of the initial diagnosis.
The standard therapy for CD infection is antibiotic treatments. Unfortunately 25% of the patients initially cured will experience recurrence. Many CD stains has become multi-resistant to antibiotics. Hence, the urgent need to develop alternative treatments that will cure patients in one treatment regime and not be the cause of further development of multi resistant bacteria.
Since early 2003, increasing rates of CD infection have been reported in Canada and the United States, with a larger proportion of severe and recurrent cases than previously reported. The raised incidence and virulence of CD infection have coincided with the spread of hypervirulent strains, particularly the ribotype NAP1/027 strain. Subsequently, epidemics of infections caused by RT 027 have been recognised in hospitals in European countries, e.g. the United Kingdom, the Netherlands, Belgium, Austria, and Sweden.